These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives. Tonni E; Oltrecolli M; Pirola M; Tchawa C; Roccabruna S; D'Agostino E; Matranga R; Piombino C; Pipitone S; Baldessari C; Bacchelli F; Dominici M; Sabbatini R; Vitale MG Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273642 [TBL] [Abstract][Full Text] [Related]
16. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605 [TBL] [Abstract][Full Text] [Related]
18. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy. Grivas P; Yu EY Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108 [TBL] [Abstract][Full Text] [Related]
19. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. Hanna KS Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332 [TBL] [Abstract][Full Text] [Related]
20. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. McGregor BA; Sonpavde G Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130 [No Abstract] [Full Text] [Related] [Next] [New Search]